Moderna (NASDAQ:MRNA) Price Target Cut to $55.00 by Analysts at Jefferies Financial Group

Moderna (NASDAQ:MRNA) had its price objective cut by Jefferies Financial Group from $65.00 to $55.00 in a report released on Tuesday morning, Benzinga reports. They currently have a hold rating on the stock.

A number of other research analysts have also recently commented on MRNA. HSBC upgraded shares of Moderna from a reduce rating to a hold rating and set a $82.00 price target on the stock in a report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a sell rating to a hold rating and dropped their target price for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. The Goldman Sachs Group dropped their target price on shares of Moderna from $178.00 to $139.00 and set a buy rating on the stock in a report on Monday, September 16th. Royal Bank of Canada reiterated a sector perform rating and set a $75.00 target price on shares of Moderna in a report on Thursday, September 19th. Finally, TD Cowen dropped their target price on shares of Moderna from $70.00 to $60.00 and set a hold rating on the stock in a report on Friday, September 13th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Moderna has a consensus rating of Hold and a consensus price target of $99.81.

Moderna Trading Down 0.7 %

MRNA stock opened at $57.31 on Tuesday. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. Moderna has a twelve month low of $55.70 and a twelve month high of $170.47. The stock has a market capitalization of $21.96 billion, a price-to-earnings ratio of -3.66 and a beta of 1.66. The firm’s fifty day simple moving average is $72.43 and its two-hundred day simple moving average is $105.61.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the previous year, the business posted ($3.62) earnings per share. The business’s revenue was down 29.9% compared to the same quarter last year. As a group, analysts anticipate that Moderna will post -9.85 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,184 shares of company stock valued at $3,804,931. 15.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Profund Advisors LLC lifted its holdings in Moderna by 20.9% in the 2nd quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock valued at $6,676,000 after purchasing an additional 9,719 shares in the last quarter. Tobam lifted its holdings in Moderna by 121.6% in the 3rd quarter. Tobam now owns 27,794 shares of the company’s stock valued at $1,857,000 after purchasing an additional 15,249 shares in the last quarter. Marshall Wace LLP lifted its holdings in Moderna by 295.5% in the 2nd quarter. Marshall Wace LLP now owns 35,200 shares of the company’s stock valued at $4,180,000 after purchasing an additional 26,300 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Moderna in the 2nd quarter valued at $4,036,000. Finally, Teachers Retirement System of The State of Kentucky lifted its holdings in Moderna by 4.3% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 283,909 shares of the company’s stock valued at $33,714,000 after purchasing an additional 11,828 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.